CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Other languages Creative Medical Technology Holdings, Inc.

Equities

CELZ

US22529Y4089

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-08 EDT			5-day change	1st Jan Change
4.43 ^USD	-3.70%		-3.17%	-3.90%

03-22	Tranche Update on Creative Medical Technology Holdings, Inc.'s Equity Buyback Plan announced on June 12, 2023.	CI
03-22	Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-22
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Type 1 Diabetes Prevention Therapy Under Expanded Access	03-07
Creative Medical Technology Holdings Gets US FDA Orphan Drug Designation; Shares Rise	03-06
Private Payrolls Data, Upcoming Powell Testimony Drive Higher Premarket Action for US Equity Futures	03-06
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Ahead of Powell Testimony	03-06
Top Premarket Gainers	03-06
Creative Medical Technology Holdings, Inc. Receives Clearance from the FDA to Conduct a Phase 1/2 Clinical Trial Using Their Innovative StemSpine Treatment Known as AlloStem	12-20
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14
Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Stemspine(R) Using Allostem(Tm) (Celz-201-Ddt) Novel Cell Therapy to Treat Chronic Lower Back Pain	23-10-10
Creative Medical Technology Holdings Receives FDA Clearance to Initiate A Phase 1/2 Clinical Trial of Stemspine® Using Allostem? (Celz-201-Ddt) for the Treatment of Chronic Lower Back Pain	23-09-19
Top Premarket Gainers	23-09-13
Top Premarket Gainers	23-08-21
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11
Top Premarket Decliners	23-06-16
Creative Medical Technology Holdings, Inc. announces an Equity Buyback for $2 million worth of its shares.	23-06-12
Creative Medical Technology Holdings, Inc. authorizes a Buyback Plan.	23-06-11
Creative Medical to Trade on 1-for-10 Reverse Stock-Split Basis Starting Monday	23-06-09
Creative Medical Technology Holdings Announces Successful Completion of the First Phase of Its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz(R) Immunotherapy Platform	23-05-31
Creative Medical Technology Holdings, Inc. Announces Next Milestone Achievements in ImmCelz Platform Development	23-05-22
Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line	23-05-18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Creative Medical Technology Holdings, Inc.

Equities

CELZ

US22529Y4089

Other languages

Filters